Detalles de la búsqueda
1.
Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.
Antimicrob Agents Chemother
; 63(6)2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30962341
2.
An Enantioselective Synthesis of a MEM-Protected Aetheramide A Derivative.
Tetrahedron Lett
; 55(37): 5191-5194, 2014 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25197148
3.
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Antimicrob Agents Chemother
; 57(5): 2036-46, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23403426
4.
Structure-based design, synthesis, and biological evaluation of dihydroquinazoline-derived potent ß-secretase inhibitors.
Bioorg Med Chem Lett
; 22(17): 5460-5, 2012 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22863204
5.
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity.
Sci Rep
; 10(1): 10664, 2020 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32606378
6.
Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
Sci Rep
; 9(1): 4828, 2019 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30886166
7.
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
J Med Chem
; 61(10): 4561-4577, 2018 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29763303
8.
Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.
ChemMedChem
; 13(8): 803-815, 2018 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29437300
9.
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
J Med Chem
; 60(10): 4267-4278, 2017 05 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28418652
10.
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.
Elife
; 62017 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-29039736
11.
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.
J Med Chem
; 56(3): 1074-83, 2013 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-23298236
12.
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
J Med Chem
; 56(10): 4017-27, 2013 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23590295
13.
Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
J Med Chem
; 53(13): 4968-79, 2010 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-20527968
14.
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
ChemMedChem
; 5(11): 1850-4, 2010 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-20827746
Resultados
1 -
14
de 14
1
Próxima >
>>